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ABSTRACT
Background and Purpose: Moyamoya vasculopathy (MMV), a rare steno-occlusive progressive
cerebrovascular disorder, has not been thoroughly studied in Caucasian populations. We established
a registry of Finnish patients treated at the Helsinki University Hospital (HUH), to collect and
report demographic and clinical data.
Methods: We collected data both retrospectively and prospectively from all the patients with a
MMV referred to our hospital between January 1987 and December 2014. All patients underwent a
neurological outpatient clinic visit.
Results: We diagnosed 61 patients (50 females, 10 children) with MMV. The mean age at the
disease-onset was 31.5 ± 17.9 years. The two most common presenting symptoms were ischemic
stroke (n=31) and hemorrhage (n=8). Forty-four per cent underwent revascularization surgery, and
70 % were prescribed antithrombotic treatment.
Conclusions: The results support in part the Western phenotype of the disease considering the later
presentation and larger female predominance compared to the Asian MMV reports. However, the
proportion of ischemic strokes and hemorrhagic strokes is closer to Japanese population than
German population. The absence of familial cases points to a different genetic profile in the Finnish
patients.




Moyamoya vasculopathy (MMV) is a rare steno-occlusive progressive cerebrovascular disorder. It
usually affects the anterior circulation, more specifically the distal portion of the internal carotid
artery and its distal branches, and only rarely the posterior cerebral arteries. Occlusion of the
anterior circulation cerebral arteries leads to formation of collateral vessels, i.e. moyamoya
vessels.(1) The term moyamoya in Japanese means a “puff of smoke” referring to the collateral
network seen on digital subtraction angiography. (2) When the disorder is idiopathic, it is referred
to as the moyamoya disease (MMD). The moyamoya syndrome (MMS), on the other hand, has the
same kind of vascular findings, but is associated with certain other conditions such as Down
syndrome, neurofibromatosis, sickle cell anemia, or head injury. (1) MMV usually peaks before the
age of 14 years and again at 31-59 years. Women are affected more often than men with a ratio
varying from 1.1-2.8:1. (3) The most common presenting symptoms are ischemic or hemorrhagic
strokes, transient ischemic attacks (TIA), headaches, and epileptic seizures. (1)
MMD is more common in Asia than in the western countries, (3) and most studies have been done
on Asian populations. Only few studies concerning the European populations have been published.
(4-9) The incidence and prevalence of MMD in Finland is not known. Furthermore, it is not known
whether the age of onset, clinical features, and many other aspects of MMV are similar to those of
the Asian populations or non-Finnish European populations. Therefore, we searched for all the
diagnosed MMD and MMS patients referred to our hospital to collect the patient data into a detailed
database, to report the patient demographics, clinical features, and treatment modalities.
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MATERIALS AND METHODS
This study was performed at the Departments of Neurology and Neurosurgery, Helsinki University
Hospital (HUH), Helsinki, Finland. The local Ethics committee approved the study
(154/13/03/00/10). The patients who came for an outpatient clinical follow-up visit gave a written
consent. For registry-based data collection, Finnish legislation does not require patient consent.
HUH is one of the five university hospitals in Finland. The population of HUH district in year 2014
was 1 599 390 as the population of Finland was 5 471 753. The Departments of Neurology and
Neurosurgery at HUH are together responsible for organizing the specialist-level care of all
neurological and neurosurgical patients in the whole HUH district. HUH Neurosurgery is the only
center in Finland where extracranial-intracranial bypass surgery is performed. All the MMV
patients in the HUH region are referred to or diagnosed at the HUH neurology department and all
the MMV patients in Finland requiring surgery are referred to the HUH neurosurgery department.
A detailed database included the patients’ medical history, family history of stroke and MMV,
medication on admission and preventive medication at discharge, hospital admission data, clinical
manifestation and time course, treatment and procedures, discharge details, outcome (modified
Rankin Scale at discharge), laboratory tests on admission, and radiological data. The radiological
data included a list of all the radiological studies done and the patterns of the ischemic lesions and
intracerebral hemorrhages (ICH), lesion sites, and vessel abnormalities. The baseline stroke risk
factors including smoking, dyslipidemia, hypertension, diabetes, and family history of stroke, were
documented.
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All patients treated between January 1987 and December 2014 were retrospectively identified from
our hospital’s electronic patient records using the diagnosis numbers 4375A, 4331A, 4331X,
4339A, 4339X, 4349A, 4349X until 1994 and the ICD 10 diagnosis number I67.5 after 1994. All
the patients diagnosed after that date were added to the database prospectively. Because our
neurological team runs the stroke center at HUH and the neurosurgical co-author (LK) is in charge
of MMV surgery in Finland, most of the patients have been seen, diagnosed, and treated by
ourselves. The diagnosis was done using methods and criteria recommended by the Japanese
guidelines(1). For this study, each patient’s diagnosis was first reviewed by MS, then discussed
with neuroradiologist JP, neurosurgeon LK, and finally with stroke neurologist TT to confirm a
consensual diagnosis. All these patients were included in our registry. Medical histories were
collected either by interviewing the patients in 2014 and 2015 at the neurological outpatient
department and/or by reviewing the patients’ hospital charts. A detailed family history was obtained
for each patient. Additionally, blood samples were collected for various future biomarker and
genetic studies. All data were inserted into an Excel-based electronic database. The incidence was
calculated by dividing the number of diagnosed MMD patients with the total population at the HUS
district per year.
Statistical analyses
Frequencies, means, and medians were analyzed using the SPSS software (IBM Corp. Released
2012. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp.).
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RESULTS
Demographic data and disease type
We identified 61 Caucasian patients of Finnish origin. Fifty-five of the 61 patients were re-
evaluated as part of this research project during years 2014 or 2015 by a neurologist (MS). Two
patients had died before being contacted and four patients did not wish to participate in the
dedicated clinical evaluation and additional tests. Most patients, (n=45, 74 %) were diagnosed with
a definite MMD, 13 (21%) with unilateral MMD, and only 3 (5%) with a MMS (Table 1). There
was a female predominance found (n=50; 82%) with only 11 (18%) male (ratio 4.5:1). At the time
of the diagnosis, 10 were children. None of the patients had family members with either MMD or
MMS. The time from the first symptoms to the diagnosis ranged from zero to 324 months. The
youngest child diagnosed was 3 years and the oldest patient was 77 years old.
Forty patients were from the HUH hospital district. The incidence of MMV in HUH district was
thus 0.14 per 100 000. The prevalence in HUCH district was 2.38 per 100 000 in year 2014.
Baseline stroke risk factors
Over one third (36%) of the patients had no cerebrovascular risk factors: almost one third (28%)
had only one single risk factor and the rest had two or more stroke risk factors. The most common
risk factor was smoking (36%), followed by hypertension (33%) and dyslipidemia (30%).
Diagnostic features
For diagnostic purposes, 75% of the patients underwent magnetic resonance angiography (MRA),
69% digital subtraction angiography (DSA), and in one case computed tomography angiography
(CTA) was performed.
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Clinical manifestations and co-morbidities
The most common clinical manifestations were ischemic stroke (51%), hemorrhage (13%), and
headaches (11%), while TIA and epileptic seizures were rare as the first presenting symptoms
(Table 1). The proportion of hemorrhage was higher in men than in women (27% vs 10%). Mean
National Institutes of Health Stroke Scale (NIHSS) at admission to hospital was 4 (range 0-32) and
median 0. Most common findings at arrival to hospital were motor and/or sensory hemiparesis and
aphasia. Single cases of diabetes insipidus, Gilbert’s syndrome, essential thrombocythemia, Crohn’s
disease, atrial septal defect, and pituitary adenoma were observed in MMV patients.
Radiological characteristics
All patients showed typical anterior circulation vasculature changes. Posterior circulation
vasculature was involved in 13% of the patients depicting various degrees of arterial changes. The
majority of the ischemic lesions (61%) were located in the anterior circulation area. Fifty-eight per
cent of patients with ischemic lesions had cortical infarcts and 77% had subcortical lesions. Fifteen
per cent were border zone infarcts. Thirty-seven per cent had bilateral infarcts. Most (67%) of the
hemorrhages were deep ICHs and the rest of the patients had subarachnoid hemorrhage. Of the deep
ICHs 33% were intraventricular hemorrhages without an intraparenchymal component. Of all the
hemorrhages, 78% had an intraventricular extension. Ten per cent of the patients carried cerebral
arterial aneurysms, 4.9% had posterior circulation aneurysms.
Treatment
Twenty-seven patients underwent revascularization surgery. Direct bypass operation was more
common than indirect operation (16 vs. 11). Seventy percent of the patients were on antithrombotic
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medication. Most of the patients used acetyl salicylic acid (ASA) only, while some had a
combination of ASA and dipyridamole, some clopidogrel alone. One patient used warfarin due to
atrial fibrillation (Table 2).
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DISCUSSION
This study is the first to report on MMV in the Finnish population. There was a higher female
predominance found than in the previously reported populations. The diagnosis was done using
methods and criteria recommended by the Japanese guidelines and according to internationally
accepted clinical practice. The later onset of disease as well as the greater female predominance,
postulated to be typical of the Western phenotype, are in line with our results (10).
The incidence and prevalence of MMV in Finland was lower compared to Japan and Korea as
expected, and close to the incidence reported in Taiwan and USA (US reports include patients with
Asian origin). The female predominance seen in both the adults and children (4.5:1) was higher
than previously reported in the Asian (11-15), North American (16,17) or German population (3:1)
(9) but close to that reported in another German population (4.25:1) (7). Mean age at the time of the
first MMV symptoms was quite the same (37.1 vs. 40.5) in our adult population as in a German
population (9), but lower in children (5.7 vs. 11.4) than previously reported. In our population,
MMV symptoms were first seen in adulthood, being equal to the German population (9), and in line
with the observations of a later manifestation of the disease in European Caucasians. The incidence
of unilateral disease in our patient population (23%) was close to that reported by the German group
(17%) (9) but twice higher than that of the Japanese (10.6%) (18). Interestingly, most of the patients
with unilateral disease were men (57%). Unfortunately, others have not reported gender distribution
information on this topic and the small number of our patients with unilateral disease allow the
possibility of a chance finding.
There was no familial MMD found in our study population. In the German population only two
patients (1.3%) had a family history of MMD (9) whereas in the Japanese population 15% had a
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family history of MMD (12). The Finnish population is genetically distinct from other European
populations due to founder effect which may explain the lack of familial cases in our study.
Smoking, hypertension, and dyslipidemia were the most common stroke risk factors in our
population. Only one-third of the patients had no risk factors which is less than the number reported
previously (7). Other co-existing diseases observed in single cases were essential thrombocythemia,
Gilbert syndrome, and Crohn’s disease. One patient had an atrial septal defect and one had a
pituitary adenoma. Essential thrombocythemia has been previously reported in two case reports
(19,20), but we could not find previous reports on Gilbert syndrome and Crohn’s disease appearing
simultaneously with MMV.
The frequencies of ischemic and hemorrhagic strokes in adult MMV patients of our study were
closer to the Japanese population than to the German population which is the largest ever-published
European study (9). We did not observe ICH in pediatric patients, but ICH occurred in adults more
often compared to the German population (15.7% vs. 7.8%). Interestingly, the frequencies of
ischemic strokes (47.1%) and hemorrhages (15.7%) in adults were closer to the numbers previously
reported in Japan (57.4% and 21%, respectively) (12) than those reported by Germans (82.8% and
7.8%) (9) or Americans (80% and 12%) (16). However, in our population men had more
hemorrhages than women which is the opposite compared to Japan (men 19.5%, women 22.2%)
(12) though the number of men in our study was quite small. We also report more patients with
headaches as the only symptom, compared to the German study.
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MMV changes in the posterior circulation were seen rarely in our patient population (13%), far less
frequently than in the German population (32%) (9). The difference was particularly great among
the pediatric patients (10 vs. 60%). The distributions of ICH, intraventricular hemorrhage, and
subarachnoid hemorrhage were the same as in the German population. We observed no arterio-
venous malformations. Cerebral aneurysms were observed in 10% of the patients, more frequently
than the 3 % reported in the German population and equal to the 10% in the North-Americans.
These differences may be merely due to small numbers.
Most of our patients received antithrombotic medication. This may be due to predominance of
ischemic events in our patient population. Antiplatelet therapy is commonly applied in Germany as
well, while its use is not common in the Asian countries (7,21). Less than half of the patients
underwent neurosurgical revascularization procedures which is a lower number than that reported in
the German study (7). The most common revascularization methods were superficial temporal
artery-middle cerebral artery (STA-MCA) bypass and encephaloduroarteriomyosynangiosis
(EDAMS) which are the most frequently employed techniques universally.
All the patients in our study were thoroughly investigated. They represent genetically a rather
homogenous population. These aspects can be considered as strengths of this study. The limitation
is the small number of patients as there is less MMV in Finland than for instance in Asia. The lack
of large series of European patients makes comparisons difficult since the large German study
included mainly surgical patients (9) and not at all patients under conservative follow-up.
Our study confirms the postulation of a Western phenotype of MMV, including a later onset of the
disease and a greater female predominance. However, it seems that the MMV patient demographics
and characteristics of the Finnish population somewhat differ from those of Germany and North
America and, in some aspects resemble more the Japanese population.
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This is the second relatively large study describing a European subpopulation. In the future, a
larger, international survey with substantially more patients would be useful to gain a better
overview of the MMV in Europe, especially if the study include detailed information on family
members and preferably coupled with genetical data.
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Table 1. Demographic data, disease type, presenting symptoms, and associated diseases.
All n=61(%) Children n=10(%) Adults n=51(%)
Female 50 (82) 8 (80) 42 (82)
Female:male ratio 4.5:1 4:1 4.6:1
Age, time of first symptoms
Mean 31.5 ± 17.9 5.7 ± 2.1 37.1 ± 14.5
Median 33 5 38
Age, time of diagnosis
Mean 34.9 ± 17.3 7.9 ± 3.9 40.2 ± 13.5
Median 38 8 41
Type of disease
    MMD 45 (74) 7 (70) 38 (75)
MMD (unilateral) 13 (21) 1 (10) 12 (23)
    MMS 3 (4.9) 2 (20) 1 (2.0)
Presenting symptoms
Ischemic 31 (51) 7 (70) 24 (47)
Hemorrhagic 8 (13) 0 8 (16)
ICH 6 (9.8) 0 6 (12)
SAH 2 (3.3) 0 2 (3.9)
TIA only 4 (6.6) 1 (10) 3 (5.9)
Seizure only 3 (4.9) 0 3 (5.9)
Headache only 7 (11) 0 7 (13)
Asymptomatic 7 (11) 2 (20) 5 (9.8)
Other 1 (1.6) 0 1 (2.0)
Associated syndromes/diseases
Neurofibromatosis type 1 1 0 1
Down's syndrome 2 2 0
MMD, moyamoya disease; MMS, moyamoya syndrome; ICH, intracerebral hemorrhage; SAH,
subarachnoid hemorrhage; TIA, transient ischemic attack
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Table 2. Summary of the surgical and antithrombotic treatment.
Total (%) Adults Children
Surgical treatment 27 (44) 17 10
Direct bypass
STA-MCA 16 16 0
Indirect bypass
EDAMS 11 1 10
Antithrombotic treatment
Aspirin 27 (46) 22(43) 5 (50)
Aspirin + Dipyridamole 6 (10) 6 (12) 0
Clopidogrel 7 (12) 5 (10) 2 (20)
Warfarin 1 (2.0) 1 (2.0) 0
None 18 (30) 15(29) 3 (30)
STA-MCA, superficial temporal artery-middle cerebral artery; EDAMS,
encephaloduroarteriomyosynangiosis
